CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Posted by Francis Steltz on Nov 10th, 2026

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $69.69.

CRSP has been the subject of a number of recent research reports. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, November 3rd. Wells Fargo & Company reduced their target price on CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 4th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, UBS Group initiated coverage on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. They issued a “neutral” rating and a $52.00 price target on the stock.

View Our Latest Report on CRISPR Therapeutics

Insider Activity at CRISPR Therapeutics

In related news, Director Simeon George sold 14,514 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total value of $720,329.82. Following the sale, the director directly owned 15,486 shares in the company, valued at approximately $768,570.18. The trade was a 48.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel James Kasinger sold 10,400 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total value of $626,496.00. Following the sale, the general counsel owned 94,784 shares of the company’s stock, valued at approximately $5,709,788.16. This trade represents a 9.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 93,558 shares of company stock valued at $4,881,663. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Compass Financial Management LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth $25,000. Versant Capital Management Inc raised its position in shares of CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after buying an additional 296 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter worth about $56,000. GAMMA Investing LLC lifted its stake in shares of CRISPR Therapeutics by 92.0% in the third quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after buying an additional 597 shares in the last quarter. Finally, Hollencrest Capital Management lifted its stake in shares of CRISPR Therapeutics by 249.9% in the first quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after buying an additional 937 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Down 0.1%

Shares of CRISPR Therapeutics stock opened at $50.04 on Tuesday. The firm’s 50 day simple moving average is $53.12 and its two-hundred day simple moving average is $52.78. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $63.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 17.85 and a current ratio of 16.21.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 25.59%. The firm had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. The company’s revenue was up 1311.1% on a year-over-year basis. As a group, analysts expect that CRISPR Therapeutics will post -4.50 earnings per share for the current fiscal year.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts.

Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.